Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, with Intravenous GTX-104 Meeting All Endpoints

Acasti Pharma Inc. announced that the top line results of its pharmacokinetic bridging study with IV GTX-104, the Company’s lead drug candidate for the treatment of Subarachnoid Hemorrhage , met all its planned study endpoints.